Related Experiment Video

Updated: Aug 29, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Cancer vaccines for the treatment and prevention of non small-cell lung cancer

M L Disis1, H L West, K Schiffman

  • 1Division of Oncology, University of Washington, Seattle 98195-6527, USA. ndisis@u.washington.edu

Clinical Lung Cancer
|January 22, 2004
PubMed

Insights

Cancer vaccines for non-small cell lung cancer (NSCLC) are being developed. Research highlights tumor antigens and immune responses, suggesting NSCLC may benefit from vaccine therapy as an adjuvant treatment.

Area of Science:

  • Immunology and Oncology
  • Molecular Biology

Background:

  • Decades of research into cancer vaccines for non-small cell lung cancer (NSCLC) have primarily utilized whole-tumor cell vaccines.
  • Recent molecular and immunological advancements have identified numerous tumor antigens crucial for generating anti-NSCLC immunity.
  • While small-cell lung cancer (SCLC) is considered immunogenic, NSCLC also elicits endogenous immune responses, potentially making it more responsive to vaccine therapy.

Purpose of the Study:

  • To review the immune system components interacting with tumor-associated proteins in NSCLC.
  • To compare the immunological characteristics of SCLC and NSCLC.
  • To discuss tumor antigens that trigger immune responses in NSCLC patients and review clinical trials of NSCLC vaccines.

Main Methods:

  • Literature review of existing research on NSCLC immunology and vaccine therapy.
  • Analysis of tumor antigens identified in NSCLC.
  • Review of clinical trial data for whole-tumor cell and antigen-specific NSCLC vaccines.

Main Results:

  • Identification of key tumor antigens involved in NSCLC immunity.
  • Understanding of NSCLC's capacity to elicit an endogenous immune response.
  • Evaluation of the potential for NSCLC vaccine therapy as an adjuvant treatment.

Conclusions:

  • NSCLC possesses characteristics that may enhance its susceptibility to vaccine-based immunotherapy.
  • Further research into tumor antigens and immune interactions is vital for developing effective NSCLC vaccines.
  • Clinical trials of both whole-tumor cell and antigen-specific vaccines are ongoing and crucial for advancing treatment strategies.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...